EN Official Journal of the European Union C 8/7

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2010

2011/C 8/07

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2010, at their meeting on 1 October 2010:

Annex I List of new marketing authorisations Annex II List of renewed marketing authorisations Annex III List of extended marketing authorisations Annex IV List of withdrawn marketing authorisations Annex V List of suspended marketing authorisations

ANNEX I List of new marketing authorisations The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2010: EU-Number Product Country Date of authorisation EU/1/06/367/001/NO-012/NO Diacomit Norway 5.2.2010 EU/1/08/476/005-006 Adcirca Liechtenstein 28.2.2010 EU/1/09/571/001/IS Pandemic Influenza Vaccine H5N1 Baxter Iceland 27.1.2010 EU/1/09/577/001/NO-004/NO Foclivia Norway 18.2.2010 EU/1/09/583/001/NO-072/NO Irbesartan/Hydrochlorothiazide Teva Norway 18.1.2010 EU/1/09/583/001-072 Irbesartan/Hydrochlorothiazide Teva Liechtenstein 28.2.2010 EU/1/09/584/001-018 Sildenafil Teva Liechtenstein 28.2.2010 EU/1/09/585/001/NO-018/NO Rivastigmine 1A Norway 9.3.2010 EU/1/09/585/001-018/IS Rivastigmine 1A Iceland 2.3.2010 EU/1/09/586/001/NO-010/NO Oslif Breezhaler Norway 27.1.2010 EU/1/09/586/001-010 Oslif Breezhaler Liechtenstein 28.2.2010 EU/1/09/587/001/NO-017/NO Olanzapine Glenmark Norway 3.2.2010 EU/1/09/587/001-017 Olanzapine Glenmark Liechtenstein 28.2.2010 EU/1/09/587/001-017/IS Olanzapine Glenmark Iceland 25.1.2010 EU/1/09/588/001/NO-012/NO Olanzapine Glenmark Europe Norway 6.2.2010 EU/1/09/588/001-012 Olanzapine Glenmark Europe Liechtenstein 28.2.2010 EU/1/09/588/001-012/IS Olanzapine Glenmark Europe Iceland 25.1.2010 EU/1/09/589/001/NO-018/NO Rivastigmine Hexal Norway 9.3.2010 EU/1/09/589/001-018 Rivastigmine Hexal Liechtenstein 28.2.2010 EU/1/09/589/001-018/IS Rivastigmine Hexal Iceland 4.3.2010 EU/1/09/590/001/NO-006/NO Prevenar 13 Norway 18.1.2010 EU/1/09/590/001-006 Prevenar 13 Liechtenstein 28.2.2010 EU/1/09/592/001/NO-005/NO Olazax Disperzi Norway 4.2.2010 EU/1/09/592/001-005 Olazax Disperzi Liechtenstein 28.2.2010 EU/1/09/592/001-005/IS Olazax Disperzi Iceland 25.1.2010 EU/1/09/593/001/NO-010/NO Onbrez Breezhaler Norway 6.1.2010 EU/1/09/593/001-010 Onbrez Breezhaler Liechtenstein 28.2.2010 EU/1/09/594/001/NO-010/NO Hirobriz Breezhaler Norway 28.1.2010 EU/1/09/594/001-010 Hirobriz Breezhaler Liechtenstein 28.2.2010 EU/1/09/595/001/NO-015/NO Sildenafil Actavis Norway 13.1.2010 EU/1/09/595/001-015/IS Sildenafil Actavis Iceland 7.1.2010 EU/1/09/596/001/NO-014/NO Lamuvidine Teva Pharma BV Norway 11.1.2010 EU/1/09/596/001-014 Lamivudine Teva Pharma BV Liechtenstein 28.2.2010 EU/1/09/596/001-014/IS Lamivudine Teva Pharma BV Iceland 1.3.2010 EU/1/09/597/001/NO-005/NO Olazax Norway 4.2.2010 EU/1/09/597/001-005/IS Olazax Iceland 25.1.2010 EU/1/09/598/001/NO-004/NO Nevirapine Teva Norway 11.1.2010 EU/1/09/598/001-004/IS Nevirapine Teva Iceland 1.3.2010 EU/1/09/599/001/NO-018/NO Rivastigmine Sandoz Norway 9.3.2010 EU/1/09/599/001-018/IS Rivastigmine Sandoz Iceland 4.3.2010 EU/1/09/600/001/IS Zutectra Iceland 24.2.2010 EU/1/09/600/001/NO Zutectra Norway 11.1.2010 EU/1/09/601/001 Zenas Liechtenstein 28.2.2010 EU/1/09/601/001/NO Zenas Norway 4.2.2010 EU/1/09/601/001/IS Zenas Iceland 20.1.2010 EU/1/09/602/001/NO-002/NO Scintimun Norway 25.1.2010 EU/1/09/602/001-002 Scintimun Liechtenstein 28.2.2010 EU/1/09/602/001-002/IS Scintimun Iceland 21.1.2010 EU/1/09/603/001/NO-012/NO Sildenafil ratiopharm Norway 13.1.2010 EU/1/09/603/001-012 Sildenafil ratiopharm Liechtenstein 28.2.2010 EU/1/09/603/001-012/IS Sildenafil ratiopharm Iceland 18.1.2010 EU/1/09/604/001/NO-010/NO Leflunomide Winthrop Norway 4.2.2010 EU/1/09/604/001-010 Leflunomide Winthrop Liechtenstein 28.2.2010 EU/1/09/604/001-010/IS Leflunomide Winthrop Iceland 22.1.2010 EU/1/09/605/001-012 Temomedac Liechtenstein 28.2.2010 EU/1/09/605/001-012/IS Temomedac Iceland 24.2.2010 EU/1/09/606/001/NO-012/NO Temozolomide Norway 15.2.2010 EU/1/09/606/001-012 Temozolomide Liechtenstein 28.2.2010 EU/1/09/606/001-012/IS Temozolomide Iceland 16.2.2010 EU/1/09/607/001/NO-014/NO Silodyx Norway 9.2.2010 EU/1/09/607/001-014 Silodyx Liechtenstein 28.2.2010 EU/1/09/607/001-014/IS Silodyx Iceland 16.3.2010 EU/1/09/608/001/NO-014/NO Urorec Norway 9.2.2010 EU/1/09/608/001-014 Urorec Liechtenstein 28.2.2010 EU/1/09/608/001-014/IS Urorec Iceland 16.3.2010 EU/1/09/609/001/NO-002/NO Elonva Norway 11.3.2010 EU/1/09/609/001-002 Elonva Liechtenstein 28.2.2010 EU/1/09/609/001-002/IS Elonva Iceland 10.2.2010 EU/1/09/610/001/NO-030/NO Telmisartan Teva Norway 2.3.2010 EU/1/09/610/001-030 Telmisartan Teva Liechtenstein 28.2.2010 EU/1/09/610/001-030/IS Telmisartan Teva Iceland 16.3.2010 EU/1/09/611/001/NO-002/NO Docetaxel Teva Norway 26.2.2010 EU/1/09/611/001-002 Docetaxel Teva Liechtenstein 28.2.2010 EU/1/09/611/001-002/IS Docetaxel Teva Iceland 23.2.2010 EU/1/10/612/001/NO-006/NO Revolade Norway 25.3.2010 EU/1/10/612/001-006 Revolade Liechtenstein 30.4.2010 EU/1/10/612/001-006/IS Revolade Iceland 7.4.2010 EU/1/10/613/001/NO-002/NO ImmunoGam Norway 19.4.2010 EU/1/10/613/001-002 ImmunoGam Liechtenstein 30.4.2010 EU/1/10/613/001-002/IS ImmunoGam Iceland 28.4.2010 EU/1/10/614/001 Menveo Liechtenstein 30.4.2010 EU/1/10/614/001/IS Menveo Iceland 15.6.2010 EU/1/10/614/001/NO Menveo Norway 21.4.2010 EU/1/10/615/001/NO-024/NO Temozolomide Hospira Norway 24.3.2010 EU/1/10/615/001-024 Temozolomide Hospira Liechtenstein 30.4.2010 EU/1/10/615/001-024/IS Temozolomide Hospira Iceland 3.5.2010 EU/1/10/616/001/NO-024/NO Temozolomide Hexal Norway 26.4.2010 EU/1/10/616/001-024 Temozolomide Hexal Liechtenstein 30.4.2010 EU/1/10/616/001-024/IS Temozolomide Hexal Iceland 27.4.2010 EU/1/10/617/001/NO-024/NO Temozolomide Sandoz Norway 26.4.2010 EU/1/10/617/001-024 Temozolomide Sandoz Liechtenstein 30.4.2010 EU/1/10/617/001-024/IS Temozolomide Sandoz Iceland 27.4.2010 EU/1/10/618/001-004 Prolia Liechtenstein 30.6.2010 EU/1/10/618/001-004/IS Prolia Iceland 23.6.2010 EU/1/10/619/001/NO-014/NO DuoPlavin Norway 23.3.2010 EU/1/10/619/001-014 DuoPlavin Liechtenstein 30.4.2010 EU/1/10/619/001-014/IS DuoPlavin Iceland 21.4.2010 EU/1/10/620/001/NO-016/NO Ristfor Norway 3.6.2010 EU/1/10/620/001-016 Ristfor Liechtenstein 30.4.2010 EU/1/10/620/001-016/IS Ristfor Iceland 5.5.2010 EU/1/10/621/001/NO-018/NO Ristaben Norway 3.6.2010 EU/1/10/621/001-018 Ristaben Liechtenstein 30.4.2010 EU/1/10/621/001-018/IS Ristaben Iceland 5.5.2010 EU/1/10/622/001/NO-002/NO Tepadina Norway 25.3.2010 EU/1/10/622/001-002/IS Tepadina Iceland 21.4.2010 EU/1/10/622/001-002 Tepadina Liechtenstein 30.4.2010 EU/1/10/623/001/NO-014/NO DuoCover Norway 23.3.2010 EU/1/10/623/001-014 DuoCover Liechtenstein 30.4.2010 EU/1/10/623/001-014/IS DuoCover Iceland 21.4.2010 EU/1/10/624/001 Arepanrix Liechtenstein 30.4.2010 EU/1/10/624/001/IS Arepanrix Iceland 21.5.2010 EU/1/10/625/001/NO-002/NO Arzerra Norway 12.5.2010 EU/1/10/625/001-002 Arzerra Liechtenstein 30.4.2010 EU/1/10/625/001-002/IS Arzerra Iceland 17.5.2010 EU/1/10/626/001/NO-004/NO Ribavirin BioPartners Norway 22.4.2010 EU/1/10/626/001-004/IS Ribavirin BioPartners Iceland 17.5.2010 EU/1/10/627/001/NO-003/NO Raloxifene Teva Norway 31.5.2010 EU/1/10/627/001-003 Raloxifene Teva Liechtenstein 30.4.2010 EU/1/10/627/001-003/IS Raloxifene Teva Iceland 18.6.2010 EU/1/10/628/001/NO-004/NO Votrient Norway 28.6.2010 EU/1/10/628/001-004 Votrient Liechtenstein 30.6.2010 EU/1/10/628/001-004/IS Votrient Iceland 28.6.2010 EU/1/10/629/001 Humenza Liechtenstein 30.6.2010 EU/1/10/629/001/IS Humenza Iceland 28.6.2010 EU/1/10/630/001/NO-002/NO Docefrez Norway 7.6.2010 EU/1/10/630/001-002 Docefrez Liechtenstein 30.6.2010 EU/1/10/630/001-002/IS Docefrez Iceland 29.6.2010 EU/1/10/631/001-009 Nivestim Liechtenstein 30.6.2010 EU/1/10/632/001-021 Tolura Liechtenstein 30.6.2010 EU/1/10/633/001/NO-002/NO Topotecan Hospira Norway 22.6.2010 EU/1/10/633/001-002 Topotecan Hospira Liechtenstein 30.6.2010 EU/1/10/634/001-004 Ribaverin Three Rivers Liechtenstein 30.6.2010 EU/1/10/634/001-004/IS Ribavirin Three Rivers Iceland 28.6.2010 EU/1/10/635/001-014 Olanzapine Apotex Liechtenstein 30.6.2010 EU/1/10/635/001-014/IS Olanzapine Apotex Iceland 28.6.2010 EU/2/08/085/001/NO Easotic Norway 4.5.2010 EU/2/08/090/001-008/IS Loxicom Iceland 23.2.2010 EU/2/09/096/001/NO-002/NO Leucogen Norway 8.2.2010 EU/2/09/101/001/NO-010/NO Zolvix Norway 8.2.2010 EU/2/09/101/001-010/IS Zolvix Iceland 4.3.2010 EU/2/09/102/001/NO-006/NO Gripovac 3 Norway 21.4.2010 EU/2/09/102/001-006 Gripovac 3 Liechtenstein 28.2.2010 EU/2/09/102/001-006/IS Gripovac 3 Iceland 4.3.2010 EU/2/09/103/001-006 Respiporc FLU3 Liechtenstein 28.2.2010 EU/2/09/103/001-006/IS Respiporc FLU3 Iceland 4.3.2010 EU/2/09/104/001/NO-002/NO Zulvac 8 Ovis Norway 11.2.2010 EU/2/09/104/001-002 Zulvac 8 Ovis Liechtenstein 28.2.2010 EU/2/09/104/001-002/IS Zulvac 8 Ovis Iceland 28.1.2010 EU/2/09/105/001/NO-002/NO Zulvac 8 Bovis Norway 8.2.2010 EU/2/09/105/001-002 Zulvac 8 Bovis Liechtenstein 28.2.2010 EU/2/09/105/001-002/IS Zulvac 8 Bovis Iceland 27.1.2010

ANNEX II List of renewed marketing authorisations The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2010: EU-Number Product Country Date of authorisation EU/1/00/129/001-003 Azopt Liechtenstein 28.2.2010 EU/1/00/129/001-003/IS Azopt Iceland 16.3.2010 EU/1/00/130/001/NO-002/NO Orgalutran Norway 8.6.2010 EU/1/00/130/001-002 Orgalutran Liechtenstein 30.6.2010 EU/1/00/130/001-002/IS Orgalutran Iceland 25.6.2010 EU/1/00/131/001/NO-005/NO PegIntron Norway 26.5.2010 EU/1/00/131/001-050 PegIntron Liechtenstein 30.6.2010 EU/1/00/131/001-050/IS PegIntron Iceland 24.6.2010 EU/1/00/132/001/NO-050/NO ViraferonPeg Norway 26.5.2010 EU/1/00/132/001-050 ViraferonPeg Liechtenstein 30.6.2010 EU/1/00/132/001-050/IS ViraferonPeg Iceland 25.6.2010 EU/1/00/133/001/NO-032/NO Optisulin Norway 25.5.2010 EU/1/00/133/001-032 Optisulin Liechtenstein 30.6.2010 EU/1/00/133/001-032/IS Optisulin Iceland 25.6.2010 EU/1/00/134/001/NO-037/NO Lantus Norway 25.5.2010 EU/1/00/134/001-037 Lantus Liechtenstein 30.6.2010 EU/1/00/134/001-037/IS Lantus Iceland 25.6.2010 EU/1/00/137/002/NO-018/NO Avandia Norway 7.6.2010 EU/1/00/137/002-012/IS Avandia Iceland 18.6.2010 EU/1/00/137/002-018 Avandia Liechtenstein 30.6.2010 EU/1/00/140/001 Visudyne Liechtenstein 30.6.2010 EU/1/00/140/001/IS Visudyne Iceland 23.6.2010 EU/1/04/272/001/NO-002/NO PhotoBarr Norway 17.2.2010 EU/1/04/294/001-028 Emselex Liechtenstein 28.2.2010 EU/1/04/298/001/NO-003/NO Kivexa Norway 19.1.2010 EU/1/04/298/001-003 Kivexa Liechtenstein 28.2.2010 EU/1/04/299/001/NO-003/NO Fendrix Norway 3.2.2010 EU/1/04/299/001-003 Fendrix Liechtenstein 28.2.2010 EU/1/04/299/001-003/IS Fendrix Iceland 7.1.2010 EU/1/04/300/001/NO-002/NO Avastin Norway 26.1.2010 EU/1/04/300/001-002 Avastin Liechtenstein 28.2.2010 EU/1/04/300/001-002/IS Avastin Iceland 11.1.2010 EU/1/04/302/001/NO-004/NO Prialt Norway 8.2.2010 EU/1/04/302/001-004 Prialt Liechtenstein 28.2.2010 EU/1/04/302/001-004/IS Prialt Iceland 17.3.2010 EU/1/04/303/001/NO-003 Orfadin Norway 3.2.2010 EU/1/04/303/001-003 Orfadin Liechtenstein 28.2.2010 EU/1/04/303/001-003/IS Orfadin Iceland 28.1.2010 EU/1/04/304/001/NO-007/NO Azilect Norway 10.2.2010 EU/1/04/305/001/NO-002/NO Truvada Norway 3.2.2010 EU/1/04/305/001-002 Truveda Liechtenstein 28.2.2010 EU/1/04/305/001-002/IS Truvada Iceland 28.1.2010 EU/1/04/306/001 Aloxi Liechtenstein 30.4.2010 EU/1/04/306/001/IS Aloxi Iceland 11.5.2010 EU/1/04/306/01/NO Aloxi Norway 23.4.2010 EU/1/04/307/001/NO-013/NO Zonegran Norway 5.2.2010 EU/1/04/307/001-013 Zonegran Liechtenstein 28.2.2010 EU/1/04/307/001-013/IS Zonegran Iceland 13.1.2010 EU/1/05/308/001/NO-002/NO Aclasta Norway 23.4.2010 EU/1/05/308/001-002 Aclasta Liechtenstein 30.4.2010 EU/1/05/308/001-002/IS Aclasta Iceland 30.4.2010 EU/1/06/367/001-012 Diacomit Liechtenstein 28.2.2010 EU/1/07/423/001-003 Vectibix Liechtenstein 30.4.2010 EU/1/07/423/001-003/IS Vectibix Iceland 7.4.2010 EU/1/07/440/001-003/IS Tyverb Iceland 30.6.2010 EU/1/10/618/001/NO-004/NO Prolia Norway 14.6.2010 EU/1/99/122/001-002 Thyrogen Liechtenstein 28.2.2010 EU/1/99/122/001-002/IS Thyrogen Iceland 19.2.2010 EU/1/99/123/005/NO-013/NO Renagel Norway 14.1.2010 EU/1/99/123/005-013 Renagel Liechtenstein 28.2.2010 EU/1/99/123/005-013/IS Renagel Iceland 5.1.2010 EU/1/99/124/001/NO-002/NO Tractocile Norway 27.1.2010 EU/1/99/124/001-002 Tractocile Liechtenstein 28.2.2010 EU/1/99/124/001-002/IS Tractocile Iceland 18.1.2010 EU/1/99/126/001/NO-021/NO Enbrel Norway 14.1.2010 EU/1/99/127/011/NO-044/NO IntronA Norway 21.4.2010 EU/1/99/127/011-039 & 041-044/IS IntronA Iceland 19.4.2010 EU/1/99/127/011-044 IntronA Liechtenstein 30.4.2010 EU/2/00/018/001 Incurin Liechtenstein 30.4.2010 EU/2/00/018/001/IS Incurin Iceland 21.4.2010 EU/2/00/018/001/NO Incurin Norway 10.5.2010 EU/2/00/019/005/NO-007/NO Purevax FeLV Norway 10.5.2010 EU/2/00/019/005-007 Purevax FeLV Liechtenstein 30.4.2010 EU/2/00/019/005-007/IS Purevax FeLV Iceland 10.5.2010 EU/2/00/021/001-002 Rabigen SAG2 Liechtenstein 30.4.2010 EU/2/00/021/001-002/IS Rabigen SAG2 Iceland 5.5.2010 EU/2/00/022/001a-001b, EU/2/00/022/002a-002b, EU/2/00/022/003a-003b, EU/2/022/004a-004b, EU/2/00/022/005-017 Ibaflin Liechtenstein 30.6.2010 EU/2/00/022/003-004 a+b&007-008/IS Ibaflin Iceland 22.6.2010 EU/2/00/022/001-002 a+b&005-006/IS Ibaflin Iceland 22.6.2010 EU/2/00/22/009-017/IS Ibaflin Iceland 22.6.2010 EU/2/04/043/001/IS Equilis StrepE Iceland 14.4.2010 EU/2/04/047/001/NO-002/NO Purevax RCPCh FeLV Norway 24.2.2010 EU/2/04/047/001-002 Purevax RCPCh FeLV Liechtenstein 28.2.2010 EU/2/04/047/001-002/IS Purevax RCPCh FeLV Iceland 15.1.2010 EU/2/04/048/001-002 Purevax RCP FeLV Liechtenstein 28.2.2010 EU/2/04/048/001-002/IS Purevax RCP FeLV Iceland 9.2.2010 EU/2/04/049/001-002 Purevax RCCh Liechtenstein 28.2.2010 EU/2/04/049/001-002/IS Purevax RCCh Iceland 9.2.2010 EU/2/04/051/001-002 Purevax RC Liechtenstein 28.2.2010 EU/2/04/051/001-002/IS Purevax RC Iceland 9.2.2010 EU/2/04/052/001-002/IS Purevax RCP Iceland 9.2.2010 EU/2/04/50/001-002/IS Purevax RCPCh Iceland 8.2.2010 EU/2/05/053/001-003 Naxcel Liechtenstein 30.6.2010 EU/2/99/013/001/NO-002/NO Halocur Norway 26.4.2010 EU/2/99/013/001-002/IS Halocur Iceland 15.3.2010 EU/2/99/017/001/NO-006/NO Ibraxion Norway 11.5.2010 EU/2/99/017/001-006/IS Ibraxion Iceland 25.5.2010

ANNEX III List of extended marketing authorisations The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2010: EU-Number Product Country Date of authorisation EU/1/00/152/019-020 Infanrix hexa Liechtenstein 30.6.2010 EU/1/00/156/004 Trizivir Liechtenstein 30.6.2010 EU/1/01/172/007 Kaletra Liechtenstein 28.2.2010 EU/1/02/205/003/NO-004/NO Lumigan Norway 12.3.2010 EU/1/02/205/003-004 Lumigan Liechtenstein 28.2.2010 EU/1/02/205/003-004/IS Lumigan Iceland 21.1.2010 EU/1/04/278/010-011 Levemir Liechtenstein 30.4.2010 EU/1/04/306/002-003 Aloxi Liechtenstein 30.6.2010 EU/1/04/306/002-003/IS Aloxi Iceland 11.5.2010 EU/1/05/318/002 Revatio Liechtenstein 28.2.2010 EU/1/05/318/002/IS Revatio Iceland 14.1.2010 EU/1/05/318/002/NO Revatio Norway 18.1.2010 EU/1/05/329/006 Kiovig Liechtenstein 30.6.2010 EU/1/06/334/005 Evoltra Liechtenstein 28.2.2010 EU/1/06/360/013 Champix Liechtenstein 28.2.2010 EU/1/07/384/003/NO-004/NO Docetaxel Winthrop Norway 1.2.2010 EU/1/07/384/003-004 Docetaxel Winthrop Liechtenstein 28.2.2010 EU/1/07/384/005 Docetaxel Winthrop Liechtenstein 30.6.2010 EU/1/07/386/017-018 Toviaz Liechtenstein 28.2.2010 EU/1/07/400/022-024 Mircera Liechtenstein 30.4.2010 EU/1/07/405/021-040 Rasilez Liechtenstein 28.2.2010 EU/1/07/411/021-026/IS Epoetin alfa Hexal Iceland 3.2.2010 EU/1/07/412/021/NO-026/NO Abseamed Norway 13.1.2010 EU/1/07/412/021-026 Abseamed Liechtenstein 28.2.2010 EU/1/07/440/003 Tyverb Liechtenstein 30.6.2010 EU/1/08/444/009-012 Ratiograstim Liechtenstein 28.2.2010 EU/1/08/445/009-014 Tevagrastim Liechtenstein 28.2.2010 EU/1/08/450/009-010 Biograstim Liechtenstein 28.2.2010 EU/1/08/453/002/NO Prepandrix Norway 9.2.2010 EU/1/08/467/002 Doribax Liechtenstein 30.4.2010 EU/1/08/467/002/IS Doribax Iceland 15.6.2010 EU/1/08/494/003-004 Stelara Liechtenstein 30.4.2010 EU/1/08/497/005/NO-008/NO Nplate Norway 2.2.2010 EU/1/08/497/005-008 Nplate Liechtenstein 28.2.2010 EU/1/08/497/005-008/IS Nplate Iceland 22.1.2010 EU/1/09/508/010 Synflorix Liechtenstein 28.2.2010 EU/1/09/525/047-050 Nimvastid Liechtenstein 30.4.2010 EU/1/09/526/002 Iressa Liechtenstein 28.2.2010 EU/1/09/528/002 Nymusa Liechtenstein 30.6.2010 EU/1/09/538/007-008 Afinitor Liechtenstein 30.4.2010 EU/1/09/540/010-016 Clopidogrel Teva Liechtenstein 30.4.2010 EU/1/09/556/010-011 Clopidogrel Krka Liechtenstein 30.4.2010 EU/1/09/557/010 Clopidogrel Qualimed Liechtenstein 30.4.2010 EU/1/09/559/010-016 Clopidogrel Mylan Liechtenstein 30.4.2010 EU/1/95/002/003/NO-004/NO Taxotere Norway 25.1.2010 EU/1/95/002/003-004 Taxotere Liechtenstein 28.2.2010 EU/1/95/002/005 Taxotere Liechtenstein 30.6.2010 EU/1/96/016/005/NO-006/NO Norvir Norway 9.2.2010 EU/1/96/016/005-006 Norvir Liechtenstein 28.2.2010 EU/1/96/016/005-006/IS Norvir Iceland 12.2.2010 EU/1/97/050/028-033 Sifrol Liechtenstein 30.6.2010 EU/1/98/069/012 Plavix Liechtenstein 30.4.2010 EU/1/98/070/012 Iscover Liechtenstein 30.4.2010 EU/1/98/080/002 Aldara Liechtenstein 30.4.2010 EU/1/98/096/024-025 Temodal Liechtenstein 28.2.2010 EU/1/97/051/028-033 Mirapexin Liechtenstein 30.6.2010 EU/2/02/032/002 Vaxxitek HVT+IBD Liechtenstein 30.6.2010 EU/2/04/044/011/NO-013/NO Aivlosin Norway 29.4.2010 EU/2/04/044/011-013 Aivlosin Liechtenstein 28.2.2010 EU/2/04/044/011-013/IS Aivlosin Iceland 7.1.2010 EU/2/06/070/004/IS Meloxidyl Iceland 25.1.2010 EU/2/06/070/005-007 Meloxidyl Liechtenstein 30.4.2010 EU/2/08/083/002-003 Equioxx Liechtenstein 28.2.2010 EU/2/08/083/002-003/IS Equioxx Iceland 11.1.2010 EU/2/08/089/021 Onsior Liechtenstein 28.2.2010 EU/2/08/090/009 Loxicom Liechtenstein 30.4.2010 EU/2/97/004/035-038 Metacam Liechtenstein 28.2.2010

ANNEX IV List of withdrawn marketing authorisations The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2010: EU-Number Product Country Date of withdrawal EU/1/00/148/001-004 Agenerase Liechtenstein 30.6.2010 EU/1/00/148/001-004/IS Agenerase Iceland 29.6.2010 EU/1/06/375/001-033 Irbesartan BMS Liechtenstein 28.2.2010 EU/1/08/471/001-012/IS Duloxetine Boehringer Ingelheim Iceland 25.6.2010 EU/1/08/471/003-005, 011-012 Duloxetine Boehringer Ingelheim Liechtenstein 30.6.2010 EU/1/99/113/001-004 Paxene Liechtenstein 28.2.2010